EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieKlinische Studie (Phase II)

Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1

Claire Booth, Julián Sevilla iD, Elena Almarza, Caroline Y Kuo, Josune Zubicaray, Dayna Terrazas, Gráinne O'Toole, Maria Chitty-Lopez, Grace Choi, Eileen Nicoletti, Janel Long-Boyle, Augustine Fernandes und 19 weitere

New England Journal of Medicine · 2025

DOI: 10.1056/nejmoa2407376 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, 2025. Verfasst von Claire Booth und 30 weiteren Autor:innen. Beteiligte Einrichtung: University College London Great Ormond Street Institute of Child Health, London. Hauptthemen laut MEDLINE: CD18 Antigens, Genetic Therapy, Lentivirus, Leukocyte-Adhesion Deficiency Syndrome. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: California Institute for Regenerative Medicine, Rocket Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD18 AntigensGenetic TherapyLentivirusLeukocyte-Adhesion Deficiency SyndromeInfectionsChildChild, PreschoolFemaleHumansInfantMaleGenetic VectorsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationTransplantation, AutologousFollow-Up StudiesMyeloablative AgonistsBusulfanTransplantation ConditioningIncidenceHospitalizationInfant, NewbornTreatment OutcomeIntegrin beta Chains

Substanzen

CD18 AntigensITGB2 protein, humanMyeloablative AgonistsBusulfanIntegrin beta Chains

Autor:innen und Institutionen

  • University College London Great Ormond Street Institute of Child Health, London.
  • Great Ormond Street Hospital NHS Foundation Trust, London.
  • Hematología y Hemoterapia, Fundación para la investigación Biomédica, Hospital Infantil Universitario Niño Jesús (HIUNJ), Madrid.
  • Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid.
  • Rocket Pharmaceuticals, Cranbury, NJ.
  • Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid.

ORCID-Profile: Julián Sevilla

Förderung

  • California Institute for Regenerative Medicine
  • Rocket Pharmaceuticals, Inc.

Zitieren

APA

Booth, C., Sevilla, J., Almarza, E., Kuo, C. Y., Zubicaray, J., Terrazas, D., O'Toole, G., Chitty-Lopez, M., Choi, G., Nicoletti, E., Long-Boyle, J., Fernandes, A., Chetty, K., De Oliveira, S., Banuelos, C., Xu-Bayford, J., Bastone, A. L., John-Neek, P., Jackson, C., …, & Kohn, D. B. (2025). Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2407376

Vancouver

Booth C, Sevilla J, Almarza E, Kuo CY, Zubicaray J, Terrazas D, et al. Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1. New England Journal of Medicine. 2025. doi:10.1056/nejmoa2407376

BibTeX
@article{Booth2025,
  author = {Booth, Claire and Sevilla, Julián and Almarza, Elena and Kuo, Caroline Y and Zubicaray, Josune and Terrazas, Dayna and O'Toole, Gráinne and Chitty-Lopez, Maria and Choi, Grace and Nicoletti, Eileen and Long-Boyle, Janel and Fernandes, Augustine and Chetty, Kritika and De Oliveira, Satiro and Banuelos, Crystal and Xu-Bayford, Jinhua and Bastone, Antonella Lucía and John-Neek, Philipp and Jackson, Connie and Moore, Theodore B and Gilmour, Kimberly and Schambach, Axel and Rothe, Michael and Kasbekar, Sanchali and Rao, Gayatri R and Patel, Kinnari and Shah, Gaurav and Thrasher, Adrian J and Bueren, Juan A and Schwartz, Jonathan D and Kohn, Donald B},
  title = {Lentiviral Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1},
  journal = {New England Journal of Medicine},
  year = {2025},
  doi = {10.1056/nejmoa2407376}
}
Kostenlos starten →